3 Undervalued Biotechnology Stocks for Thursday, October 03
Discover the top 3 undervalued Biotechnology stocks for Thursday, October 03 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Commentary & Analysis
3 Undervalued Medical Equipment, Supplies & Distribution Stocks for Monday, September 02
Discover the top 3 undervalued Medical Equipment, Supplies & Distribution stocks for Monday, September 02 based on AAII’s Stock Grades.Omar Beirat
3 Undervalued Medical Equipment, Supplies & Distribution Stocks for Wednesday, July 31
Discover the top 3 undervalued Medical Equipment, Supplies & Distribution stocks for Wednesday, July 31 based on AAII’s Stock Grades.Omar Beirat
4 Undervalued Medical Equipment, Supplies & Distribution Stocks for Monday, July 01
Discover the top 4 undervalued Medical Equipment, Supplies & Distribution stocks for Monday, July 01 based on AAII’s Stock Grades.Grace Malone
5 Undervalued Medical Equipment, Supplies & Distribution Stocks for Wednesday, May 22
Discover the top 5 undervalued Medical Equipment, Supplies & Distribution stocks for Wednesday, May 22 based on AAII’s Stock Grades.Jenna Brashear
Financial Summary
| Share Statistics | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.3 | $223.5 | 1% |
|
| Shares Out (Mil) | 3.7 | 53.4 | 12% |
|
| Institutional Ownership | 99.5% | 92.9% | 89% |
|
| Float (Mil) | 2.8 | 40.4 | 7% |
|
| Beta | 0.57 | 0.96 | 32% |
|
| Avg Daily Volume (000s) | 32 | 463 | 26% |
|
| Price Change (52-week) |
(82.8%) | 45.9% | 8% |
|
| Growth | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (11.5%) | (10.1%) | 28% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.150) | ($1.180) | ($0.590) | |
| Month Ago EPS | ($0.180) | ($1.230) | ($0.670) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.170) | ($1.170) | ($0.640) | |
| Year/Year Chg | (9.1%) | (55.4%) | na | |
| Financials | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($3) | ($44) | 35% |
|
| EPS (TTM) | ($1.244) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($33) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($5) | $173 | 2% |
|
| Valuation | BBLG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.21 | 2.08 | 4% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | BBLG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (44.5%) | (47.0%) | 13% |
|
| ROE | (47.5%) | (52.7%) | 16% |
|
| Liabilities to Assets | 7.5% | 29.6% | 4% |
|
| F-Score | 2 | 2 | 7% |
|
Bone Biologics Corporation did not pass any screens on 11/2/2026.
